Granted Patent B2

US 12,239,766 · App. 18/364,476 · Granted Mar 4, 2025

Inventors: Orahn Preiss-Bloom (Zichron Yakov, IL); Taly Pnina Lindner (Savyon, IL); Eyal Epstein (Tel Aviv, IL); Danielle Poreh (Herzliyya, IL)

Assignee: OSSIO LTD.

A61L31/128A61B17/864A61B17/866A61F2/4455A61F2/447A61L27/446A61L27/58A61L31/06A61L31/08A61L31/148A61F2002/30062A61F2002/30593A61F2002/4495

Abstract

Claims (36)

1. A medical implant comprising a biocomposite; wherein the biocomposite comprises a polymer and a plurality of continuous reinforcement fibers; wherein the fibers are aligned in plurality of fiber bundles; wherein said fibers are uni-directionally aligned within each fiber bundle; wherein said polymer is biodegradable and said implant is bioabsorbable; wherein said continuous fibers are longer than 4 mm; and wherein a distance between adjacent reinforcing fibers within the bundle is in the range of 0.5.50 μm.

2. The implant of claim 1 , wherein said continuous fibers are longer than 8 mm, 12 mm, 16 mm or 20 mm.

3. The implant of claim 1 , wherein a reinforcing fiber length of at least a portion of said fibers is at least 50% of a longitudinal length of the implant.

4. The implant of claim 3 , wherein said reinforcing fiber length of a majority of said fibers is at least 50%, at least 60% or at least 75% of said longitudinal length of the implant.

5. The implant of claim 1 , wherein a majority of reinforcement fibers within the composite layer are aligned at an angle to the longitudinal axis, wherein said angle is less than 90°, less than 60°, or less than 45° from the longitudinal axis.

6. The implant of claim 1 , wherein a diameter of said fibers is in a range of 0.1-100 μm, 1-20 μm, 4-16 μm, 6-20 μm, 10-18 μm, or 14-16 μm.

7. The implant claim 1 , wherein a standard deviation of fiber diameter between fibers is less than 5 μm, less than 3 μm, or less than 1.5 μm.

8. The implant of claim 1 , wherein a weight percentage of fibers is in a range of 20-90%, or a range of 40%-70%.

9. The implant of claim 1 , wherein a volume percentage of reinforcing fibers within the implant is in a range of 30-90%, or a range of 40%-70%.

10. The implant of claim 1 , wherein a density of the biocomposite is between 1 to 2 g/ml, between 1.2 to 1.9 g/ml, or between 1.4 to 1.8 g/ml.

11. The implant of claim 1 , wherein the implant has a flexural modulus exceeding 10 GPa and flexural strength exceeding 100 MPa.

12. The implant of claim 11 , wherein said implant has flexural strength in a range of 400-800 MPa, or a range of 650-800 MPa.

13. The implant of claim 11 , wherein said implant has an elastic modulus in a range of 10-27 GPa, or a range of 16-27 GPa.

14. The implant of claim 1 , wherein said biodegradable polymer comprises a homopolymer or a copolymer; wherein said copolymer comprises a random copolymer, block copolymer, or graft copolymer; wherein said polymer comprises a linear polymer, a branched polymer, or a dendrimer, of natural or synthetic origin; and wherein said polymer comprises comprises lactide, glycolide, caprolactone, valerolactone, carbonates (e.g., trimethylene carbonate, tetramethylene carbonate, and the like), dioxanones (e.g., 1,4-dioxanone), δ-valerolactone, 1, dioxepanones) e.g., 1,4-dioxepan-2-one and 1,5-dioxepan-2-one), ethylene glycol, ethylene oxide, esteramides, γ-ydroxyvalerate, β-hydroxypropionate, alpha-hydroxy acid, hydroxybuterates, poly (ortho esters), hydroxy alkanoates, tyrosine carbonates, polyimide carbonates, polyimino carbonates such as poly (bisphenol A-iminocarbonate) and poly (hydroquinoneiminocarbonate, (polyurethanes, polyanhydrides, polymer drugs (e.g., polydiflunisol, polyaspirin, and protein therapeutics), sugars; starch, cellulose and cellulose derivatives, polysaccharides, collagen, chitosan, fibrin, hyaluronic acid, polypeptides, proteins, poly (amino acids), polylactides (PLA), poly-L-lactide (PLLA), poly-DL-lactide (PDLLA); polyglycolide (PGA); copolymers of glycolide, glycolide/trimethylene carbonate copolymers (PGA/TMC); other copolymers of PLA, such as lactide/tetra methylglycolide copolymers, lactide/trimethylene carbonate copolymers, lactide/d-valerolactone copolymers, lactide/E-caprolactone copolymers, L-lactide/DL-lactide copolymers, glycolide/L-lactide copolymers (PGA/PLLA), polylactide-co-glycolide; terpolymers of PLA, such as lactide/glycolide/trimethylene carbonate terpolymers, lactide/glycolide/E-caprolactone terpolymers, PLA/polyethylene oxide copolymers; polydepsipeptides; unsymmetrically-3,6-substituted poly-1,4-dioxane-2,5-diones; polyhydroxyalkanoates; such as polyhydroxybutyrates (PHB); PHB/b-hydroxyvalerate copolymers (PHB/PHV); poly-b-hydroxypropionate (PHPA); poly-p-dioxanone (PDS); poly-d-valerolactone-poly-E-capralactone, poly (E-caprolactone-DL-lactide) copolymers; methylmethacrylate-N-vinyl pyrrolidone copolymers; polyesteramides; polyesters of oxalic acid; polydihydropyrans; polyalkyl-2-cyanoacrylates; polyurethanes (PU); polyvinylalcohol (PVA); polypeptides; poly-b-malic acid (PMLA): poly-b-alkanbic acids; polycarbonates; polyorthoesters; polyphosphates; poly (ester anhydrides); and mixtures thereof; and derivatives, copolymers and mixtures thereof.

15. The implant of claim 14 , wherein said polymer is selected from the group consisting of PLLA, PDLA, PGA, PLGA, PCL, PLLA-PCL and a combination thereof.

16. The implant of claim 15 , wherein said PLLA is used in said polymer matrix and said matrix comprises at least 30% PLLA.

17. The implant of claim 15 , wherein said PDLA is used in said polymer matrix and said matrix comprises at least at least 5% PDLA, least 10% PDLA, or at least 20% PDLA.

18. The implant of claim 1 , wherein said fiber comprises a silica-based mineral compound.

19. The implant of claim 18 , wherein said silica-based mineral compound has at least one oxide composition in at least one of the following mol. % ranges:

Na 2 O: 11.0-19.0 mol. %

CaO: 9.0-14.0 mol. %

MgO: 1.5-8.0 mol. %

B 2 O 3 : 0.5-3.0 mol. %

Al 2 O 3 : 0-0.8 mol. % and

P 2 O 3 : 0.1-0.8 mol. %.

20. The implant of claim 19 , wherein said silica-based mineral compound has at least one oxide composition in at least one of the following mol. % ranges:

Na 2 O: 12.0-13.0 mol. %

CaO: 9.0-10.0 mol. %

MgO: 7.0-8.0 mol. %

B 2 O 3 : 1.4-2.0 mol. %

P 2 O 3 : 0.5-0.8 mol. % and

SiO 2 : 68-70 mol. %.

21. A method of treatment for an orthopedic application in a subject in need of treatment thereof, comprising implanting to the subject the medical implant of claim 1 .

22. A medical implant comprising a biocomposite; wherein the biocomposite comprises a polymer and a plurality of continuous reinforcement fibers; wherein the fibers are aligned in plurality of fiber bundles; wherein said fibers are uni-directionally aligned within each fiber bundle; wherein said polymer is biodegradable and said implant is bioabsorbable; wherein said continuous fibers are longer than 4 mm; and wherein a distance between adjacent reinforcing fibers within the bundle is in the range of 0.5-50 μm; and wherein a density of the biocomposite is between 1 to 2 g/ml, between 1.2 to 1.9 g/ml, or between 1.4 to 1.8 g/ml.

23. A medical implant comprising a biocomposite; wherein the biocomposite comprises a polymer and a plurality of continuous reinforcement fibers; wherein the fibers are aligned in plurality of fiber bundles; wherein said fibers are uni-directionally aligned within each fiber bundle; wherein said polymer is biodegradable and said implant is bioabsorbable; wherein said continuous fibers are longer than 4 mm; and wherein a distance between adjacent reinforcing fibers within the bundle is in the range of 0.5-50 μm; and wherein a weight percentage of fibers in the implant is in a range of 20-90%, or a range of 40%-70%.

24. A medical implant comprising a biocomposite; wherein the biocomposite comprises a polymer and a plurality of continuous reinforcement fibers; wherein the fibers are aligned in plurality of fiber bundles; wherein said fibers are uni-directionally aligned within each fiber bundle; wherein said polymer is biodegradable and said implant is bioabsorbable; wherein said continuous fibers are longer than 4 mm; and wherein a distance between adjacent reinforcing fibers within the bundle is in the range of 0.5-50 μm; and wherein said implant has flexural strength in a range of 400-800 MPa, or a range of 650-800 MPa.

Assignments (4)

Continuity (4)

References Cited (290)